Drug intelligence / Profile preview

vic-trastuzumab duocarmazine + paclitaxel

Development stage: Unknown
Lead developer: Byondis
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

vic-trastuzumab duocarmazine + paclitaxel is a combination therapy under investigation for the treatment of HER2-positive cancers, particularly metastatic breast cancer. Vic-trastuzumab duocarmazine (SYD985) is an antibody-drug conjugate (ADC) that consists of the monoclonal antibody trastuzumab linked to a cleavable cytotoxic payload, valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA). The ADC binds to HER2 on tumor cells and, upon internalization and proteolytic cleavage, releases an active DNA-damaging agent that induces tumor cell death. Paclitaxel is a taxane-class small molecule chemotherapeutic that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and thereby inhibiting mitosis and inducing apoptosis in cancer cells. This combination aims to leverage both targeted delivery of cytotoxin via the ADC and broad antimitotic activity from paclitaxel[1][3][5][6].

Brand names: Vic
Other names: trastuzumab duocarmazine[vic]-trastuzumab duocarmazine

Targets

TUBB (Tubulin (alpha and beta subunits))DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on vic-trastuzumab duocarmazine + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vic-trastuzumab duocarmazine + paclitaxel.

Explore the full profile